Waldenstrom Macroglobulinemia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of WM and LPL for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s WM and LPL forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with WM and LPL per year?
- Of all people diagnosed with WM and LPL, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of WM and LPL over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following WM and LPL subpopulations:
- Diagnosed incident cases of Waldenstrom macroglobulinemia.
- Diagnosed incident cases of lymphoplasmacytic lymphoma.
- Diagnosed prevalent cases of Waldenstrom macroglobulinemia.
- Diagnosed prevalent cases of lymphoplasmacytic lymphoma.
- Diagnosed incident cases by treatment status.
Note: Coverage may vary by country.
Table of contents
- Waldenstrom Macroglobulinemia - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Overview
- Incidence of Waldenstrom Macroglobulinemia per 100,000 People of All Ages in 2021 and 2041tttttt
- Incidence of Lymphoplasmacytic Lymphoma per 100,000 People of All Ages in 2021 and 2041tttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Waldenstrom Macroglobulinemia Over the Next 20 Yearstttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Lymphoplasmacytic Lymphoma Over the Next 20 Yearstttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Incident Cases
- Diagnosed Prevalent Cases
- Drug-Treatable and Drug-Treated Populations
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma
- Studies Excluded From the Analysis of Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma
- Risk/Protective Factors
- Risk/Protective Factors for Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma
- Abbreviations
- Glossary
- Bibliography
- Literature Review
- Introduction
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.